注意欠陥多動性障害(ADHD)治療の世界市場規模・現状・予測2021年-2027年

QYResearchが発行した調査報告書(QY21APR0503)
◆英語タイトル:Global Attention Deficit Hyperactivity Disorder Therapeutics Market Size, Status and Forecast 2021-2027
◆商品コード:QY21APR0503
◆発行会社(リサーチ会社):QYResearch
◆発行日:2021年4月
◆ページ数:109
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:医薬品、ヘルスケア
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,900 ⇒換算¥499,200見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD5,850 ⇒換算¥748,800見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はQYResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。

本調査資料では、注意欠陥多動性障害(ADHD)治療の世界市場(2016年~2027年)を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模(刺激剤、非刺激剤)、用途別市場規模(病院薬局、小売薬局)、主要地域別市場規模(北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等)、企業情報などをまとめております。
・市場概要
・注意欠陥多動性障害(ADHD)治療の市場動向
・企業の競争状況、市場シェア
・注意欠陥多動性障害(ADHD)治療の種類別市場規模(刺激剤、非刺激剤)
・注意欠陥多動性障害(ADHD)治療の用途別市場規模(病院薬局、小売薬局)
・注意欠陥多動性障害(ADHD)治療の北米市場規模2016-2027(アメリカ、カナダ)
・注意欠陥多動性障害(ADHD)治療の欧州市場規模2016-2027(ドイツ、フランス、イギリス等)
・注意欠陥多動性障害(ADHD)治療のアジア市場規模2016-2027(日本、中国、韓国、インド、東南アジア等)
・注意欠陥多動性障害(ADHD)治療の中南米市場規模2016-2027(メキシコ、ブラジル)
・注意欠陥多動性障害(ADHD)治療の中東・アフリカ市場規模2016-2027(トルコ、サウジアラビア等)
・主要企業情報(Takeda、Johnson & Johnson、Novartis、Eli Lilly、Tris Pharma、Neos Therapeutics、Mallinckrodt、Amneal Pharmaceuticals、Noven Pharmaceuticals、Purdue Parma)
・結論
【レポートの概要】

Attention deficit hyperactivity disorder (ADHD) is a mental health disorder that can cause above-normal levels of hyperactive and impulsive behaviors.

Market Analysis and Insights: Global Attention Deficit Hyperactivity Disorder Therapeutics Market
The global Attention Deficit Hyperactivity Disorder Therapeutics market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Attention Deficit Hyperactivity Disorder Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Attention Deficit Hyperactivity Disorder Therapeutics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Attention Deficit Hyperactivity Disorder Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Attention Deficit Hyperactivity Disorder Therapeutics market.

Global Attention Deficit Hyperactivity Disorder Therapeutics Scope and Market Size
Attention Deficit Hyperactivity Disorder Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Attention Deficit Hyperactivity Disorder Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Stimulant
Non-stimulant

Segment by Application
Hospital Pharmacy
Retail Pharmacy

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Takeda
Johnson & Johnson
Novartis
Eli Lilly
Tris Pharma
Neos Therapeutics
Mallinckrodt
Amneal Pharmaceuticals
Noven Pharmaceuticals
Purdue Parma

【レポートの目次】

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Attention Deficit Hyperactivity Disorder Therapeutics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Stimulant
1.2.3 Non-stimulant
1.3 Market by Application
1.3.1 Global Attention Deficit Hyperactivity Disorder Therapeutics Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Attention Deficit Hyperactivity Disorder Therapeutics Market Perspective (2016-2027)
2.2 Attention Deficit Hyperactivity Disorder Therapeutics Growth Trends by Regions
2.2.1 Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Attention Deficit Hyperactivity Disorder Therapeutics Historic Market Share by Regions (2016-2021)
2.2.3 Attention Deficit Hyperactivity Disorder Therapeutics Forecasted Market Size by Regions (2022-2027)
2.3 Attention Deficit Hyperactivity Disorder Therapeutics Industry Dynamic
2.3.1 Attention Deficit Hyperactivity Disorder Therapeutics Market Trends
2.3.2 Attention Deficit Hyperactivity Disorder Therapeutics Market Drivers
2.3.3 Attention Deficit Hyperactivity Disorder Therapeutics Market Challenges
2.3.4 Attention Deficit Hyperactivity Disorder Therapeutics Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Attention Deficit Hyperactivity Disorder Therapeutics Players by Revenue
3.1.1 Global Top Attention Deficit Hyperactivity Disorder Therapeutics Players by Revenue (2016-2021)
3.1.2 Global Attention Deficit Hyperactivity Disorder Therapeutics Revenue Market Share by Players (2016-2021)
3.2 Global Attention Deficit Hyperactivity Disorder Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Attention Deficit Hyperactivity Disorder Therapeutics Revenue
3.4 Global Attention Deficit Hyperactivity Disorder Therapeutics Market Concentration Ratio
3.4.1 Global Attention Deficit Hyperactivity Disorder Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Attention Deficit Hyperactivity Disorder Therapeutics Revenue in 2020
3.5 Attention Deficit Hyperactivity Disorder Therapeutics Key Players Head office and Area Served
3.6 Key Players Attention Deficit Hyperactivity Disorder Therapeutics Product Solution and Service
3.7 Date of Enter into Attention Deficit Hyperactivity Disorder Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Attention Deficit Hyperactivity Disorder Therapeutics Breakdown Data by Type
4.1 Global Attention Deficit Hyperactivity Disorder Therapeutics Historic Market Size by Type (2016-2021)
4.2 Global Attention Deficit Hyperactivity Disorder Therapeutics Forecasted Market Size by Type (2022-2027)

5 Attention Deficit Hyperactivity Disorder Therapeutics Breakdown Data by Application
5.1 Global Attention Deficit Hyperactivity Disorder Therapeutics Historic Market Size by Application (2016-2021)
5.2 Global Attention Deficit Hyperactivity Disorder Therapeutics Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Attention Deficit Hyperactivity Disorder Therapeutics Market Size (2016-2027)
6.2 North America Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Type
6.2.1 North America Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Type (2016-2021)
6.2.2 North America Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Type (2022-2027)
6.2.3 North America Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Type (2016-2027)
6.3 North America Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Application
6.3.1 North America Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Application (2016-2021)
6.3.2 North America Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Application (2022-2027)
6.3.3 North America Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Application (2016-2027)
6.4 North America Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Country
6.4.1 North America Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Country (2016-2021)
6.4.2 North America Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Attention Deficit Hyperactivity Disorder Therapeutics Market Size (2016-2027)
7.2 Europe Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Type
7.2.1 Europe Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Type (2016-2021)
7.2.2 Europe Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Type (2022-2027)
7.2.3 Europe Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Type (2016-2027)
7.3 Europe Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Application
7.3.1 Europe Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Application (2016-2021)
7.3.2 Europe Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Application (2022-2027)
7.3.3 Europe Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Application (2016-2027)
7.4 Europe Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Country
7.4.1 Europe Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Country (2016-2021)
7.4.2 Europe Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Attention Deficit Hyperactivity Disorder Therapeutics Market Size (2016-2027)
8.2 Asia-Pacific Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Type
8.2.1 Asia-Pacific Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Type (2016-2027)
8.3 Asia-Pacific Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Application
8.3.1 Asia-Pacific Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Application (2016-2027)
8.4 Asia-Pacific Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Region
8.4.1 Asia-Pacific Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Attention Deficit Hyperactivity Disorder Therapeutics Market Size (2016-2027)
9.2 Latin America Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Type
9.2.1 Latin America Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Type (2016-2021)
9.2.2 Latin America Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Type (2022-2027)
9.2.3 Latin America Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Type (2016-2027)
9.3 Latin America Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Application
9.3.1 Latin America Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Application (2016-2021)
9.3.2 Latin America Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Application (2022-2027)
9.3.3 Latin America Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Application (2016-2027)
9.4 Latin America Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Country
9.4.1 Latin America Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Country (2016-2021)
9.4.2 Latin America Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Attention Deficit Hyperactivity Disorder Therapeutics Market Size (2016-2027)
10.2 Middle East & Africa Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Type
10.2.1 Middle East & Africa Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Type (2016-2027)
10.3 Middle East & Africa Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Application
10.3.1 Middle East & Africa Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Application (2016-2027)
10.4 Middle East & Africa Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Country
10.4.1 Middle East & Africa Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Takeda
11.1.1 Takeda Company Details
11.1.2 Takeda Business Overview
11.1.3 Takeda Attention Deficit Hyperactivity Disorder Therapeutics Introduction
11.1.4 Takeda Revenue in Attention Deficit Hyperactivity Disorder Therapeutics Business (2016-2021)
11.1.5 Takeda Recent Development
11.2 Johnson & Johnson
11.2.1 Johnson & Johnson Company Details
11.2.2 Johnson & Johnson Business Overview
11.2.3 Johnson & Johnson Attention Deficit Hyperactivity Disorder Therapeutics Introduction
11.2.4 Johnson & Johnson Revenue in Attention Deficit Hyperactivity Disorder Therapeutics Business (2016-2021)
11.2.5 Johnson & Johnson Recent Development
11.3 Novartis
11.3.1 Novartis Company Details
11.3.2 Novartis Business Overview
11.3.3 Novartis Attention Deficit Hyperactivity Disorder Therapeutics Introduction
11.3.4 Novartis Revenue in Attention Deficit Hyperactivity Disorder Therapeutics Business (2016-2021)
11.3.5 Novartis Recent Development
11.4 Eli Lilly
11.4.1 Eli Lilly Company Details
11.4.2 Eli Lilly Business Overview
11.4.3 Eli Lilly Attention Deficit Hyperactivity Disorder Therapeutics Introduction
11.4.4 Eli Lilly Revenue in Attention Deficit Hyperactivity Disorder Therapeutics Business (2016-2021)
11.4.5 Eli Lilly Recent Development
11.5 Tris Pharma
11.5.1 Tris Pharma Company Details
11.5.2 Tris Pharma Business Overview
11.5.3 Tris Pharma Attention Deficit Hyperactivity Disorder Therapeutics Introduction
11.5.4 Tris Pharma Revenue in Attention Deficit Hyperactivity Disorder Therapeutics Business (2016-2021)
11.5.5 Tris Pharma Recent Development
11.6 Neos Therapeutics
11.6.1 Neos Therapeutics Company Details
11.6.2 Neos Therapeutics Business Overview
11.6.3 Neos Therapeutics Attention Deficit Hyperactivity Disorder Therapeutics Introduction
11.6.4 Neos Therapeutics Revenue in Attention Deficit Hyperactivity Disorder Therapeutics Business (2016-2021)
11.6.5 Neos Therapeutics Recent Development
11.7 Mallinckrodt
11.7.1 Mallinckrodt Company Details
11.7.2 Mallinckrodt Business Overview
11.7.3 Mallinckrodt Attention Deficit Hyperactivity Disorder Therapeutics Introduction
11.7.4 Mallinckrodt Revenue in Attention Deficit Hyperactivity Disorder Therapeutics Business (2016-2021)
11.7.5 Mallinckrodt Recent Development
11.8 Amneal Pharmaceuticals
11.8.1 Amneal Pharmaceuticals Company Details
11.8.2 Amneal Pharmaceuticals Business Overview
11.8.3 Amneal Pharmaceuticals Attention Deficit Hyperactivity Disorder Therapeutics Introduction
11.8.4 Amneal Pharmaceuticals Revenue in Attention Deficit Hyperactivity Disorder Therapeutics Business (2016-2021)
11.8.5 Amneal Pharmaceuticals Recent Development
11.9 Noven Pharmaceuticals
11.9.1 Noven Pharmaceuticals Company Details
11.9.2 Noven Pharmaceuticals Business Overview
11.9.3 Noven Pharmaceuticals Attention Deficit Hyperactivity Disorder Therapeutics Introduction
11.9.4 Noven Pharmaceuticals Revenue in Attention Deficit Hyperactivity Disorder Therapeutics Business (2016-2021)
11.9.5 Noven Pharmaceuticals Recent Development
11.10 Purdue Parma
11.10.1 Purdue Parma Company Details
11.10.2 Purdue Parma Business Overview
11.10.3 Purdue Parma Attention Deficit Hyperactivity Disorder Therapeutics Introduction
11.10.4 Purdue Parma Revenue in Attention Deficit Hyperactivity Disorder Therapeutics Business (2016-2021)
11.10.5 Purdue Parma Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details



【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 注意欠陥多動性障害(ADHD)治療の世界市場規模・現状・予測2021年-2027年(Global Attention Deficit Hyperactivity Disorder Therapeutics Market Size, Status and Forecast 2021-2027)]についてメールでお問い合わせはこちらでお願いします。